Q2 2023 Holdings
Filed 2023-08-14 | 34 holdings | $496.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Oncology, Inc.(CGEM) | Common | 230031106 | $82.3M | 7,648,268 | 16.6% |
| Iveric Bio Inc(OPHTEUR) | Common | 46583P102 | $47.8M | 1,214,662 | 9.6% |
| Chinook Therapeutics, Inc.(290A) | Common | 16961L106 | $38.6M | 1,003,406 | 7.8% |
| Geron Corporation(GERN) | Common | 374163103 | $29.5M | 9,191,290 | 5.9% |
| Reata Pharmaceuticals, Inc.(RETAEUR) | Common | 75615P103 | $23.9M | 234,478 | 4.8% |
| iTeos Therapeutics, Inc.(5E7) | Common | 46565G104 | $23.1M | 1,745,943 | 4.7% |
| Intellia Therapeutics, Inc.(NTLA) | Common | 45826J105 | $22.2M | 544,639 | 4.5% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $20.8M | 2,950,118 | 4.2% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $17.3M | 1,639,849 | 3.5% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $17.0M | 1,354,368 | 3.4% |
| Verve Therapeutics, Inc | Common | 92539P101 | $16.1M | 857,940 | 3.2% |
| Moonlake Immunotherapeutics(MLTX) | Common | 61559X104 | $15.1M | 295,111 | 3.0% |
| Regenxbio Inc.(RGNX) | Common | 75901B107 | $13.1M | 656,718 | 2.6% |
| Karuna Therapeutics Inc | Common | 48576A100 | $11.6M | 53,399 | 2.3% |
| Insmed Incorporated(INSM) | Common | 457669307 | $11.2M | 529,743 | 2.3% |
| Xeris Biopharma Holdings Inc(XERS) | Common | 98422E103 | $10.4M | 3,974,999 | 2.1% |
| Madrigal Pharmaceuticals inc(MDGL) | Common | 558868105 | $8.8M | 38,011 | 1.8% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $8.6M | 479,053 | 1.7% |
| Travere Therapeutics Inc.(TVTX) | Common | 89422G107 | $8.5M | 552,846 | 1.7% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $7.3M | 273,408 | 1.5% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $7.3M | 2,388,011 | 1.5% |
| Kalvista Pharmaceuticals Inc(KALV) | Common | 483497103 | $6.9M | 761,538 | 1.4% |
| Axsome Therapeutics, Inc.(AXSM) | Common | 05464T104 | $6.7M | 93,586 | 1.4% |
| Amicus Therapeutics Inc.(FOLD) | Common | 03152W109 | $6.5M | 516,139 | 1.3% |
| Avadel Pharmaceuticals PLC | Sponsored ADR | 05337M104 | $6.3M | 384,990 | 1.3% |
| Viridian Therapeutics Inc(VRDN) | Common | 92790C104 | $6.1M | 255,323 | 1.2% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $5.5M | 712,798 | 1.1% |
| Adaptimmune Therapeutics plc(ADAPY) | Common | 00653A107 | $4.7M | 5,095,912 | 0.9% |
| Olema Pharmaceuticals, Inc.(OLMA) | Common | 68062P106 | $4.2M | 462,500 | 0.8% |
| Phathom Pharmaceuticals inc(PHAT) | Common | 71722W107 | $4.0M | 282,332 | 0.8% |
| Harpoon Therapeutics, Inc. | Common | 41358P106 | $2.3M | 3,196,707 | 0.5% |
| Inozyme Pharma Inc. | Common | 45790W108 | $1.8M | 326,921 | 0.4% |
| Ventyx Biosciences Inc(VTYX) | Common | 92332V107 | $1.0M | 31,747 | 0.2% |
| Oncorus, Inc. | Common | 68236R103 | $96.3K | 2,377,031 | 0.0% |